Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar
about
Optimal Synthetic Glycosylation of a Therapeutic AntibodyOptimal Synthetic Glycosylation of a Therapeutic AntibodyMethods to Make Homogenous Antibody Drug Conjugates.Eliminating antibody polyreactivity through addition of N-linked glycosylation.Immunomodulatory Response Triggered by the Alkaloids, 3-Amino-7-Benzylbenzimidazo[3,2-a] Quinolinium Chloride (ABQ-48) and 3-Nitro-7-Benzylbenzimidazo [3,2-a] Quinolinium Chloride (NBQ-48)Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.Antibody Therapeutics in Oncology.Stable and Potent Selenomab-Drug Conjugates.Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.Emerging site-specific bioconjugation strategies for radioimmunotracer development.Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality ControlHarnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugatesCrystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.Straightforward Glycoengineering Approach to Site-Specific Antibody-Pyrrolobenzodiazepine Conjugates.Solid-Phase Enzymatic Remodeling Produces High Yields of Single Glycoform Antibodies.Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody-drug conjugates.One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates.N-terminal α-amino group modification of antibodies using a site-selective click chemistry method.Site-Specific Antibody Conjugation for ADC and Beyond.
P2860
Q28831266-F4BFAF81-8D89-4929-9B3F-2AD1024F9ED9Q28831364-2BF0B34F-0369-498A-B827-6993B9FFE45FQ35523479-CD84D57D-8D20-4849-809F-7A48C35AAAF2Q35684786-6A2C1922-232A-478D-8E62-553BA47E8D81Q35743952-CC150DED-3166-4AA6-A72D-E76C2F4E4406Q35952586-E699B737-B174-4566-A9F7-98A7F6DF4348Q36791878-C03CC0D2-1EA5-4A2F-9E1D-73AB3187B05DQ38432502-528D22A6-ECA0-4EEE-94C3-1E1218599208Q38708078-E119E3A2-DCF7-4EC8-99EA-6D7BBF3AB52AQ38818208-7DCFFBE3-2867-4F5C-B473-87C7890EAF5EQ41353023-476E47D5-6F30-4BF7-8C91-A9FC5B632A8BQ42646020-465B0A62-3A74-4905-AD9D-AD32D0805431Q44852748-EE657028-A39F-4305-ADCC-8AE4775DEC1BQ46809979-5E57C8D2-A1C4-477D-9899-BE9F1CFB5359Q47286747-12BBC9D5-EFB5-4300-AAAA-A95905904E78Q47816782-59EF6B9A-5669-47F5-8CDE-2D9A6AED0E71Q47874093-00199D0F-63F5-42C2-9FC3-9148FE77DBC5Q48987144-74BB9183-2600-48A3-A8C8-7840D63917E6Q52590082-CFC23251-EED0-4594-B220-343249F14ABFQ55022669-2178BA70-52D1-42EF-A87C-C88CE761CC29
P2860
Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Site-specific antibody-drug co ...... nd a chemically reactive sugar
@ast
Site-specific antibody-drug co ...... nd a chemically reactive sugar
@en
type
label
Site-specific antibody-drug co ...... nd a chemically reactive sugar
@ast
Site-specific antibody-drug co ...... nd a chemically reactive sugar
@en
prefLabel
Site-specific antibody-drug co ...... nd a chemically reactive sugar
@ast
Site-specific antibody-drug co ...... nd a chemically reactive sugar
@en
P2093
P2860
P356
P1476
Site-specific antibody-drug co ...... nd a chemically reactive sugar
@en
P2093
Boopathy Ramakrishnan
Dimiter S Dimitrov
Marzena A Dyba
Ponraj Prabakaran
Pradman K Qasba
Simona Colantonio
Yanping Wang
Zhongyu Zhu
P2860
P304
P356
10.4161/MABS.29889
P577
2014-10-30T00:00:00Z